Moderna and Merck announce advances in cancer vaccine research. Moderna shifted focus toward cancer treatments, driving its stock up 177%. The company developed a tailored mRNA injection designed to combat skin cancer, though its effectiveness remains uncertain. Merck developed a cancer vaccine that could usher in a wave of comparable therapies.
Views on these developments vary. Some people attribute success to market driven innovation, while others view it as an overdue advance. Further study is needed to properly assess the implications of these findings. Still, the results point to encouraging progress in cancer treatment.